Last reviewed · How we verify
pravastatin, valsartan, pravastatin+valsartan
Pravastatin inhibits HMG-CoA reductase to lower cholesterol, while valsartan blocks angiotensin II receptors to reduce blood pressure; the combination addresses both lipid and hypertension management.
Pravastatin inhibits HMG-CoA reductase to lower cholesterol, while valsartan blocks angiotensin II receptors to reduce blood pressure; the combination addresses both lipid and hypertension management. Used for Hypertension with dyslipidemia, Cardiovascular risk reduction in patients requiring both statin and ARB therapy.
At a glance
| Generic name | pravastatin, valsartan, pravastatin+valsartan |
|---|---|
| Sponsor | Gachon University Gil Medical Center |
| Drug class | Statin + Angiotensin II Receptor Blocker (ARB) combination |
| Target | HMG-CoA reductase (pravastatin); Angiotensin II Type 1 receptor (valsartan) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Pravastatin is a statin that reduces LDL cholesterol by inhibiting the rate-limiting enzyme in cholesterol synthesis. Valsartan is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking vasoconstriction and aldosterone secretion. Together, they provide complementary cardiovascular protection by addressing dyslipidemia and hypertension simultaneously.
Approved indications
- Hypertension with dyslipidemia
- Cardiovascular risk reduction in patients requiring both statin and ARB therapy
Common side effects
- Muscle pain or myalgia
- Dizziness
- Hyperkalemia
- Elevated liver enzymes
- Cough
Key clinical trials
- Detoxification From the Lipid Tract (PHASE4)
- Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia (PHASE4)
- Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168) (PHASE3)
- Additive Effects of Pravastatin and Valsartan (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: